Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
The
study was designed a long time ago, and it was designed at a time
when there was increasing interest in ovarian ablation because of
the metaanalysis and also because there were now drugs that were
available that could lead to chemical castration as opposed to surgical
ablation. So, the thought was that perhaps in premenopausal, node-positive,
receptor-positive breast cancers – so women who were likely
predisposed to respond to hormone therapy but also who had reasonable
risk of recurrence – that we would look at questions related
to chemo-hormonal therapy. So the randomization was to six cycles
of CAF, which was the pretty standard chemotherapy then, or on the
second group, six cycles of CAF followed by five years of goserelin
– Zoladex, an LHRH agonist. The 3rd arm got the
six cycles of CAF followed by the goserelin and the tamoxifen. And,
of course, in the best of all worlds we would have had a 4th
arm that got CAF followed by tamoxifen, but at the time it was felt
that we weren’t sure that we could pull it off statistically
– that we could accrue to that trial in a timely fashion and
have something to talk about.
Combined
endocrine therapy for breast cancer - New life for an old idea? Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute 92(11):859-860, 2000 Jun 7. No
abstract
